Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Sixth Affiliated Hospital, Sun Yat-sen University
Updated on 4 October 2022


This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.

Condition Advanced Esophageal Cancer
Treatment Combination Therapy, SHR-1210 + paclitaxel + cisplatin
Clinical Study IdentifierNCT05174156
SponsorSixth Affiliated Hospital, Sun Yat-sen University
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Unresectable locally advanced/ recurrent or distant metastatic esophageal squamous cell carcinoma confirmed by histology or cytology
Not received any previous systematic antitumor therapy
Eastern Cooperative Oncology Group (ECOG) fitness status score was 0 or 1 within 3 days before the first administration of the intervention
-10 tumor tissue samples can be provided
Demonstrate good organ and bone marrow function
Consent to participate in the contraceptive methods related to clinical research

Exclusion Criteria

Have a history of allergy to monoclonal antibodies, any component of SHR-1210, albumin-paclitaxel, carboplatin, and other platinum drugs
Weight loss > 20% in the past 3 months
Major surgery within 28 days prior to enrollment
Have received systemic chemotherapy or radiation therapy for esophageal cancer
Had a myocardial infarction within the past 6 months
Have any medical history or current evidence, treatment, or laboratory abnormalities that prevent the subject from participating fully in the study with the investigator's opinion
Prior treatment with immunotherapy drugs
Received live vaccine within 30 days prior to initial administration of the investigational drug
Have been diagnosed with immunodeficiency or are receiving immunosuppressive treatment
Another malignancy is known to exist
Have active infections that require systemic treatment
Pregnant or lactating, or planning to become pregnant or become a father during the study period (180 days for lactating subjects receiving carboplatin) from the beginning of the screening visit until 120 days after the last dose of the study intervention
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note